Peter Carmeliet
From Wikipedia, the free encyclopedia
Peter Carmeliet is a Belgian MD and professor at the Katholieke Universiteit Leuven (Leuven, Belgium). He is also Adjunct Director of the Department of Transgene Technology and Gene Therapy of the VIB. One of his research interests are vasculogenesis, angiogenesis and Vascular endothelial growth factor (VEGF)[1][2]. In 2002, he was awarded the Francqui Prize on Biological and Medical Sciences. Together with Désiré Collen, he was awarded the Interbrew-Baillet Latour Health Prize in 2005.
[edit] References
- ^ Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature 380, 435-439, 1996
- ^ Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, J. Hillan K, W. Moore M, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature 380, 439-442, 1996
[edit] External links
This Belgian biographical article is a stub. You can help Wikipedia by expanding it.
